Sphere Fluidics
Sphere Fluidics is an established Life Sciences company providing single cell analysis and monoclonality assurance systems for biotherapeutic discovery and development.
Sphere Fluidics Cyto-Mine®, is a fully integrated device which can accelerate biologics discovery and cell line development by streamlining cell isolation, assay, sorting, imaging and dispensing into one automated process which reduces timelines, increases screening capabilities and assures monoclonality.
Cyto-Mine®, underpinned by the Companys patented picodroplet technology, integrates selective screening of tens of millions of single cells in miniaturised aqueous pL compartments called picodroplets. Within the picodroplets, single cells are assayed to identify valuable proteins (e.g. antibodies) to find rare cells of interest or cells with high productivity. Cyto-Mine® can selectively sort the hits and during subsequent dispensing into individual microtitre plate wells, image the picodroplets for assurance of monoclonality.
Cyto-Mine® provides a solution to resource-intensive, time-consuming and expensive workflows by streamlining cell isolation, titre determination and clonality assurance while reducing costs for biopharmaceutical discovery and development. Using picodroplet microfluidic technology, Sphere Fluidics is developing a novel system that will automate and miniaturise many of the steps in the single cell engineering using synthetic biology or genome editing, to enhance the generation of high-quality precision engineered cells in a high-throughput manner.
Sphere Fluidics has 30 employees based in labs and offices in Babraham (Cambridgeshire, UK) and Monmouth Junction (New Jersey, USA) and has signed international distributorships in all other major markets.
- 1
- 2
Sphere Fluidics Strengthens Commercial Team With Three New Senior Hires
Cambridge, UK, 10 May 2022: Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed three new hires to its commercial team. Evelyn Stevenson and Ravi Girdhar join as Director of Product Management and Director of Sales (EMEA), respectively, alongside Denise Emsden as Vice-President...
Sphere Fluidics introduces latest version of Cyto-Mine Studio Software Suite
Cambridge, UK, 27 August 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced an updated version of its Cyto-Mine Studio Software Suite, a collection of software controlling operation of its Cyto-Mine Single Cell Analysis System, data acquisition and follow-up analysis. The latest software version includes new...
Sphere Fluidics expands into additional facility at Granta Park in Cambridge, UK
New offices at leading science hub support the Companyís rapid growth following recent investment New facility is in addition to headquarters at Babraham Research Campus, Cambridgeshire, UK and offices in Monmouth Junction, New Jersey, USA
CPI to showcase results from BioStreamline project developing novel biotherapeutics
CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners ó Lonza...
Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round
Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for...
Fujifilm Announces The Introduction Of A 10 Week Cell Line Development Timeline With Its Apollo™ X Advanced Mammalian Expression System
FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies, has announced the reduction of cell line development timelines with its Apollo X™ Advanced Mammalian Expression System.
- 1
- 2
The Jonas Webb Building, Babraham Research Campus, Babraham, Cambridge CB22 3AT, United Kingdom
+44 1223 804200
